01—Abstract
Summary
Summary of the 8-K filed February 1, 2024. Cited figures are marked; the original filing is the authoritative source.
BD reported fiscal Q1 2024 (quarter ended December 31, 2023) revenue of $4.706 billiona, up 2.6% as reported, 1.6% currency-neutral, and 2.4% organic.
Growth was led by BD Interventional (+5.2% reported, +8.4% organic), with BD Medical up 3.5% and BD Life Sciences down 1.0%. International sales grew 5.5% reported, while U.S. sales grew only 0.7%. Profitability was weaker on a GAAP basis: GAAP diluted EPS fell 43.5% to $0.96b and net income fell 44.8% to $281 million, driven largely by $362 million of pre-tax purchase accounting charges, higher restructuring costs ($69 million), and a $111 million interest expense load.
Adjusted diluted EPS was $2.68c, down 10.1% reported and 2.0% currency-neutral, and cost of products sold rose 9.2% against 2.6% revenue growth. Management raised its fiscal 2024 outlook. Revenue guidance moved to $20.2-20.4 billion from $20.1-20.3 billion, organic growth to 5.5%-6.25% (the low end and midpoint were raised), and adjusted EPS to $12.82-13.06 from $12.70-13.00.
The EPS raise reflects a 7-cent operational improvement and a 2-cent currency benefit at the midpoint. Guidance still absorbs roughly 75 basis points of drag from the Surgical Instrumentation divestiture and roughly 360 basis points of FX headwind to adjusted EPS growth, which is expected to be about 5%d-7%. Cash flow and capital returns were stronger than the earnings line implied.
Operating cash flow was $855 million versus $399 million a year earlier, and capital expenditures were $116 million, leaving roughly $739 million of free cash flow. BD repurchased $500 million of common stock and paid $275 million in dividends. Cash fell to $1.18 billion and total debt (current plus long-term) was about $16.1 billion, up from about $15.9 billion at September 30, 2023.
Shareholders' equity declined to $25.3 billion. Management's outlook is contingent on the Alaris infusion system's return to the U.S. market, which remains subject to FDA engagement and customer readiness.
02—Key points
Key Highlights
- Q1 FY2024 revenue of $4.706 billion grew 2.6% reported, 1.6% currency-neutral, and 2.4% organic; U.S. grew 0.7% while International grew 5.5% reported.
- GAAP diluted EPS fell 43.5% to $0.96 and net income fell 44.8% to $281 million, reflecting $362 million of pre-tax purchase accounting charges and $69 million of restructuring costs; adjusted diluted EPS was $2.68, down 10.1%.
- Cost of products sold rose 9.2% versus 2.6% revenue growth, and operating income fell 24.9% to $439 million, signaling margin pressure on a GAAP basis.
- FY2024 guidance was raised: revenue to $20.2-20.4 billion, organic growth to 5.5%-6.25%, and adjusted EPS to $12.82-13.06 (about 5%-7% growth, including roughly 360 bps of FX headwind).
- BD Interventional was the standout segment, growing 5.2% reported and 8.4% organically, driven by Surgery (Phasix hernia scaffold, ChloraPrep) and Peripheral Intervention; BD Life Sciences declined 1.0% on IDS weakness (down 4.1%) after prior-year respiratory testing.
- Operating cash flow nearly doubled to $855 million, and BD returned capital through $500 million of share repurchases and $275 million of dividends.
- Cash declined to $1.18 billion and total debt was about $16.1 billion, leaving the balance sheet more levered after the quarter, while the Alaris infusion system's U.S. return remains a key execution risk.
03—Questions
Frequently Asked Questions
Why did GAAP EPS fall so sharply if revenue grew?
GAAP diluted EPS dropped 43.5% to $0.96 mainly because of $362 million in pre-tax purchase accounting adjustments (about $1.24 per share), plus restructuring costs of $69 million and other special items. Cost of products sold grew 9.2%, faster than revenue. BD's adjusted EPS of $2.68 excludes these items, which management views as outside ordinary operations, though investors should weigh GAAP results alongside adjusted figures.
Did BD actually raise its outlook for fiscal 2024?
Yes. Revenue guidance rose to $20.2-20.4 billion from $20.1-20.3 billion, organic growth moved to 5.5%-6.25% from 5.25%-6.25% (low end and midpoint raised), and adjusted EPS guidance increased to $12.82-13.06 from $12.70-13.00. Management attributed the EPS increase at the midpoint mostly to operational strength in Q1 (7 cents) plus a 2-cent currency benefit.
What is driving the divergence between U.S. and international performance?
International revenue grew 5.5% reported (2.9% currency-neutral), led by Interventional (+11.2%) and Life Sciences (+6.7%). U.S. revenue grew only 0.7%, with Life Sciences down 9.0% (IDS down 12.6%) offsetting growth in Medical (+4.4%) and Interventional (+2.5%). The IDS decline reflects a tough comparison to elevated prior-year respiratory testing revenue.
How strong is BD's cash generation and balance sheet after this quarter?
Operating cash flow of $855 million, less $116 million of capex, implies roughly $739 million of free cash flow, and BD returned about $775 million through buybacks and dividends. However, cash fell to $1.18 billion and total debt rose to about $16.1 billion, so leverage is a watch item. Management's leverage and capital deployment plans were referenced as forward-looking topics for the earnings call.
What are the key risks to the fiscal 2024 outlook?
Key risks include the timing of the Alaris infusion system's return to the U.S. market, which depends on customer readiness, supply continuity, and FDA engagement; China's volume-based procurement and related pricing pressure; weakness in IDS and anticoagulant demand; the roughly 75 bps drag from the Surgical Instrumentation divestiture; and FX headwinds of about 360 bps to adjusted EPS growth. Outlook also assumes no major charges outside the adjusted metrics, which can be large and hard to predict.
04—Continue